S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Options trading has suddenly become more reliable. (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
1970’s computer coder issues shocking A.I. warning (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Options trading has suddenly become more reliable. (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
1970’s computer coder issues shocking A.I. warning (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Options trading has suddenly become more reliable. (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
1970’s computer coder issues shocking A.I. warning (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
S&P 500   5,051.41
DOW   37,798.97
QQQ   431.10
Stock market today: Most of Wall Street slips as expectations rise for rates to stay high
The "Smart Money" Is Ready for May 1st Are You? (Ad)
Kinder Morgan Stock Bid Up In An Oil Breakout
ASML’s Earnings Could Bring The Stock to New Highs
Options trading has suddenly become more reliable. (Ad)
3 Computer Vision Stocks for Long-Term Gains From AI
Undervalued UnitedHealth Group Won’t Be For Long
1970’s computer coder issues shocking A.I. warning (Ad)
Closing prices for crude oil, gold and other commodities
DocuSign and The Case for 66% Upside 
Free Trial
NASDAQ:GEMP

Gemphire Therapeutics (GEMP) Stock Price, News & Analysis

→ Could Bitcoin Literally FORCE This Crypto To Rocket Up? (From Paradigm Press) (Ad)
Free GEMP Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$3.49
▼
$3.73
50-Day Range
$0.30
▼
$6.38
52-Week Range
$0.24
▼
$1.49
Volume
22,921 shs
Average Volume
127,174 shs
Market Capitalization
$52.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsSocial Media
GEMP stock logo

About Gemphire Therapeutics Stock (NASDAQ:GEMP)

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.

GEMP Stock News Headlines

May 11, 2023 | marketwatch.com
Hypertriglyceridemia Treatment Market Detect New Industry Opportumities 2023-2030
April 28, 2023 | marketwatch.com
Nonalcoholic Steatohepatitis (NASH) Market 2023: Share and Growth Opportunities Forecast till 2030
April 16, 2024 | Paradigm Press (Ad)
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
April 12, 2023 | marketwatch.com
2023-2031 Non-Alcoholic Steatohepatitis Market: Latest Updates
April 12, 2023 | marketwatch.com
2023-2031 Non-Alcoholic Steatohepatitis Market: Latest Updates
March 29, 2023 | marketwatch.com
Nonalcoholic Steatohepatitis (NASH) Market Growth and Industry Insights till 2027
March 26, 2023 | marketwatch.com
Global Hypercholesterolemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2023-2030 By VMReports
March 24, 2023 | marketwatch.com
2023 Hypertriglyceridemia Treatment Market Size, Growth | Global Industry Trends [2029]
April 16, 2024 | Paradigm Press (Ad)
Could Bitcoin Literally FORCE This Crypto To Rocket Up?
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
March 2, 2023 | marketwatch.com
Hypertriglyceridemia Treatment Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2029
March 1, 2023 | marketwatch.com
Hypertriglyceridemia Treatment Market 2023 Growth, Trends With the Rise in ICT Industry 2029
February 17, 2023 | marketwatch.com
Latest Hypertriglyceridemia Treatment Market Research Report (2023-2028)-Key Takeaways from Top Companies
February 15, 2023 | marketwatch.com
Worldwide Nonalcoholic Steatohepatitis (NASH) Market 2023 with Growth Analysis by Size and Share to 2027 | 99 Pages
January 24, 2023 | finance.yahoo.com
BiVictriX Therapeutics makes 'fundamental step forward'
April 6, 2022 | marketwatch.com
Hypertriglyceridemia Treatment Market Size 2022 Analysis Growth Report by Trends, Applications, Types, Competitive Strategies and Forecast to 2029
March 31, 2022 | marketwatch.com
Global Hypercholesterolemia Treatment Market 2022 Opportunity Assessment, Key Drivers and Challenges, Growth Rate and Forecast to 2028
October 13, 2021 | markets.businessinsider.com
NeuroBo Pharma: DMC Recommends Continuation Of Phase 2/3 Trial Of ANA001 Without Modification
See More Headlines
Receive GEMP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gemphire Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/15/2019
Today
4/16/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GEMP
CUSIP
N/A
CIK
1638287
Web
www.gemphire.com
Phone
734-245-1700
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-23,640,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-419.70%
Return on Assets
-173.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.67
Quick Ratio
0.67

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
6.54

Miscellaneous

Outstanding Shares
14,872,000
Free Float
N/A
Market Cap
$52.50 million
Optionable
Not Optionable
Beta
2.82
Investing Strategies To Help Grow Your Retirement Income Cover
Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Charles L. Bisgaier (Age 65)
    Co-Founder, Chairman & Chief Scientific Officer
  • Dr. Steven R. Gullans (Age 66)
    CEO, Pres, Director, Principal Financial Officer & Principal Accounting Officer
  • Mr. Seth Reno (Age 52)
    Chief Commercial Officer
  • Mr. Jeffrey S. Mathiesen C.P.A. (Age 58)
    CPA, Consultant
  • Ms. Amy Zaremba Rabourn
    Director of Fin.

Key Competitors

View All Competitors

GEMP Stock Analysis - Frequently Asked Questions

How were Gemphire Therapeutics' earnings last quarter?

Gemphire Therapeutics Inc (NASDAQ:GEMP) released its earnings results on Friday, March, 15th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.15.

What other stocks do shareholders of Gemphire Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Gemphire Therapeutics investors own include AcelRx Pharmaceuticals (ACRX), Micron Technology (MU), Pixelworks (PXLW), SCYNEXIS (SCYX), Alexion Pharmaceuticals (ALXN), Clearside Biomedical (CLSD), Intel (INTC), Iovance Biotherapeutics (IOVA) and Melinta Therapeutics (MLNT).

When did Gemphire Therapeutics IPO?

Gemphire Therapeutics (GEMP) raised $30 million in an initial public offering on Friday, August 5th 2016. The company issued 3,000,000 shares at $10.00 per share. Jefferies and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Roth Capital Partners were co-managers.

This page (NASDAQ:GEMP) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
New Trump Bombshell
The Freeport Society
Top 5 Tech Stocks to Buy for 2024
Daily Market Alerts